Endocuff Vision (Norgine Pharmaceuticals) is a single-use, disposable device which fits over the end of most conventional colonoscopes. It is designed to increase the diagnostic sensitivity of colonoscopy investigation by increasing the total surface area of the visual field. Evidence supports the case for adopting Endocuff Vision in the NHS because it improves the adenoma detection rate during colonoscopy, particularly for people having a colonoscopy as part of bowel cancer screening.
Endocuff Vision should be considered as an option for people having a colonoscopy as part of bowel cancer screening following a positive stool test. There is limited evidence for the benefits of Endocuff Vision in a non-screening population.
Cost modelling shows that for people having a colonoscopy as part of bowel cancer screening, using Endocuff Vision is cost saving. Savings are related to the adenoma detection rate; for a colonoscopist with a baseline adenoma detection rate of 51%, using Endocuff Vision saves £53 per patient over 10 years compared with standard colonoscopy.